Table 4.
Assessment of quality of evidence by the Grades of Recommendation, Assessment, Development and Evaluation system
| Outcome: rheumatoid arthritis-associated interstitial lung disease | ||||||||||
| Prognostic factors | Analysis | GRADE factors | ||||||||
| Phase | Study limitations | Inconsistency | Indirectness | Publication bias | Imprecision | Moderate/large effect size | Dose effect | Overall quality | ||
| Anti-CCP antibody positivity | Univariate | 1 | + | + | – | + | – | – | – | Very low |
| Multivariate | 1 | + | + | – | + | – | – | – | Very low | |
| Anti-CCP antibody titre | Univariate | 1 | + | + | – | + | – | – | – | Very low |
| Multivariate | 1 | + | – | – | + | – | – | + | Low | |
CCP, cyclic citrullinated peptite;GRADE, Grades of Recommendation, Assessment, Development and Evaluation.